Frontiers in public health · 2026
Analysis of nationwide availability of negotiated drugs in China's National Reimbursement Drug List.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yumeng, Zhang Wenqi, Deng Jizuoni, Liu Yuhan, Sun Lihua
Аннотация
OBJECTIVE: This study aims to evaluate the availability of Price-Negotiated Drugs under China's National Reimbursement Drug List in healthcare institutions and designated retail pharmacies.
METHODS: This cross-sectional study uses data from the National Health Insurance Service Platform (extracted in September 2025) to evaluate the availability of 383 National Negotiated Drugs in healthcare institutions and retail pharmacies nationwide. According to the World Health Organization (WHO)/Health Action International (HAI) framework, availability was assessed based on the availability rate and allocation rate. Spearman's rank correlation test (α = 0.05) was applied to examine associations between drug availability and factors including the timing of formulary inclusion, per capita disposable income, regional gross domestic product (GDP), the number of relevant policy releases and Pharmacists, the accumulated balance of health insurance funds, and the average annual number of visits per person.
RESULTS: The overall availability of negotiated drugs was low, with mean availability rates of 2.08% in healthcare institutions and 0.13% in designated retail pharmacies. Although drugs were predominantly concentrated in tertiary hospitals, their average availability there remained modest at 9.84%. Substantial provincial disparities were observed in the allocation of tertiary hospitals, with the eastern regions showing relatively higher rates. Drugs added to the formulary earlier and those with higher clinical demand were more available. Spearman's correlation analysis indicated significant associations between drug availability and timing of formulary inclusion (r = -0.53, p < 0.001), per capita disposable income (r = 0.45, p = 0.012), regional GDP (r = 0.49, p = 0.005), the number of relevant policy releases (r = 0.57, p < 0.001), the number of Pharmacists (r = 0.43, p = 0.017), the accumulated balance of health insurance funds (r = 0.61, p < 0.001), and the average annual number of visits per person (r = 0.62, p < 0.001).
CONCLUSION: According to the WHO/HAI standards, the overall availability of negotiated drugs in China remains relatively low, with notable institutional stratification and regional disparities. This finding suggests that policy efforts should focus on strengthening supply incentives and promoting rational drug use. Additionally, policymakers should consider the differences across regions and institutions when advancing drug availability to ensure equitable access to medicines.
METHODS: This cross-sectional study uses data from the National Health Insurance Service Platform (extracted in September 2025) to evaluate the availability of 383 National Negotiated Drugs in healthcare institutions and retail pharmacies nationwide. According to the World Health Organization (WHO)/Health Action International (HAI) framework, availability was assessed based on the availability rate and allocation rate. Spearman's rank correlation test (α = 0.05) was applied to examine associations between drug availability and factors including the timing of formulary inclusion, per capita disposable income, regional gross domestic product (GDP), the number of relevant policy releases and Pharmacists, the accumulated balance of health insurance funds, and the average annual number of visits per person.
RESULTS: The overall availability of negotiated drugs was low, with mean availability rates of 2.08% in healthcare institutions and 0.13% in designated retail pharmacies. Although drugs were predominantly concentrated in tertiary hospitals, their average availability there remained modest at 9.84%. Substantial provincial disparities were observed in the allocation of tertiary hospitals, with the eastern regions showing relatively higher rates. Drugs added to the formulary earlier and those with higher clinical demand were more available. Spearman's correlation analysis indicated significant associations between drug availability and timing of formulary inclusion (r = -0.53, p < 0.001), per capita disposable income (r = 0.45, p = 0.012), regional GDP (r = 0.49, p = 0.005), the number of relevant policy releases (r = 0.57, p < 0.001), the number of Pharmacists (r = 0.43, p = 0.017), the accumulated balance of health insurance funds (r = 0.61, p < 0.001), and the average annual number of visits per person (r = 0.62, p < 0.001).
CONCLUSION: According to the WHO/HAI standards, the overall availability of negotiated drugs in China remains relatively low, with notable institutional stratification and regional disparities. This finding suggests that policy efforts should focus on strengthening supply incentives and promoting rational drug use. Additionally, policymakers should consider the differences across regions and institutions when advancing drug availability to ensure equitable access to medicines.